What is the clinical evidence from this study?

Study design: Other. Population: Thrombin-induced thromboembolism. Intervention: Activated human protein C (APC) vs. Vehicle/saline. Primary outcome: Mortality (>85% reduction, p=<0.008).

February 1, 1998Journal of Clinical InvestigationOpen Access

Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.

Q: What are the key findings of this study?

Activated human protein C administered intravenously before thrombin challenge reduced mortality by over 85% in a mouse model of acute intravascular fibrin deposition.

View Full Paper

Ask AI

Bookmark

Key result

Activated human protein C administered intravenously before thrombin challenge reduced mortality by over 85% in a mouse model of acute intravascular fibrin deposition.

Why the study?

Does activated protein C prevent mortality in a mouse model of thrombin-induced thromboembolism?

Population

Male CD-1 mice weighing 20-25 g

Comparison

Human activated protein C administered… vs Vehicle/saline administered intravenously 2…

Design

Preclinical, Pathologist unaware of the treatment administered to the animals

Follow-up

15 minutes

Authors

PGPaolo GreseleVascular Medicine SMStefania MomiUniversity of Perugia MBMauro BerrettiniScripps Research Institute

Discussion

Member takes

Overview

Hypothesis-generating for activated protein C in thromboembolism; should not yet change clinical practice pending human trials.

Structured PICO

Does activated protein C prevent mortality in a mouse model of thrombin-induced thromboembolism?

Population

Male CD-1 mice weighing 20-25 g subjected to a model of acute thrombin-induced pulmonary thromboembolism.

Intervention

Human activated protein C (APC) administered intravenously as a bolus (doses up to 2 mg/kg) 2 minutes before thrombin challenge (1,250 U/kg)

Comparator

Vehicle/saline administered intravenously 2 minutes before thrombin challenge

Outcome

Mortality (death or prolonged paralysis of the hind limbs within 15 minutes)hard clinical

Main Result

Effect estimate: >85% reduction

Absolute Event Rate: 12% vs 80%

p-value: p=<0.008

Activated protein C prevents thrombin-induced thromboembolism and death in mice by inhibiting endogenous thrombin generation, thereby facilitating endogenous fibrinolysis.

Limitations

Animal model may not fully translate to human pathology
Short observation period of 15 minutes

Cite This Study

Gresele et al. (1998) studied Thrombin-induced thromboembolism. Activated human protein C (APC) vs. Vehicle/saline was evaluated on Mortality (>85% reduction, p=<0.008). Activated human protein C administered intravenously before thrombin challenge reduced mortality by over 85% in a mouse model of acute intravascular fibrin deposition.

synapsesocial.com/papers/6a93eb2d5e7ae87f038f985e https://doi.org/10.1172/jci575

View Full Paper

Ask AI

Bookmark

February 1, 1998Journal of Clinical InvestigationOpen Access

Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.

View Full Paper

Ask AI

Bookmark

Key result

Activated human protein C administered intravenously before thrombin challenge reduced mortality by over 85% in a mouse model of acute intravascular fibrin deposition.

Why the study?

Does activated protein C prevent mortality in a mouse model of thrombin-induced thromboembolism?

Population

Male CD-1 mice weighing 20-25 g

Comparison

Human activated protein C administered… vs Vehicle/saline administered intravenously 2…

Design

Preclinical, Pathologist unaware of the treatment administered to the animals

Follow-up

15 minutes

Authors

PGPaolo GreseleVascular Medicine SMStefania MomiUniversity of Perugia MBMauro BerrettiniScripps Research Institute

Discussion

Member takes

Overview

Hypothesis-generating for activated protein C in thromboembolism; should not yet change clinical practice pending human trials.

Structured PICO

Does activated protein C prevent mortality in a mouse model of thrombin-induced thromboembolism?

Population

Male CD-1 mice weighing 20-25 g subjected to a model of acute thrombin-induced pulmonary thromboembolism.

Intervention

Human activated protein C (APC) administered intravenously as a bolus (doses up to 2 mg/kg) 2 minutes before thrombin challenge (1,250 U/kg)

Comparator

Vehicle/saline administered intravenously 2 minutes before thrombin challenge

Outcome

Mortality (death or prolonged paralysis of the hind limbs within 15 minutes)hard clinical

Main Result

Effect estimate: >85% reduction

Absolute Event Rate: 12% vs 80%

p-value: p=<0.008

Activated protein C prevents thrombin-induced thromboembolism and death in mice by inhibiting endogenous thrombin generation, thereby facilitating endogenous fibrinolysis.

Limitations

Animal model may not fully translate to human pathology
Short observation period of 15 minutes

Cite This Study

synapsesocial.com/papers/6a93eb2d5e7ae87f038f985e https://doi.org/10.1172/jci575

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark